8-K: LENSAR Exceeds ALLY Placement Targets, Reports Strong Revenue Growth in Q4 and Full Year 2023

LENSAR, Inc. announced strong financial results for the fourth quarter and full year 2023, driven by increased sales of its ALLY Adaptive Cataract Treatment System.

Summary

• LENSAR reported a successful fourth quarter and full year 2023, with total revenue increasing by 18% in Q4 and 19% for the full year compared to 2022.
• The company significantly exceeded its target for ALLY system placements, installing 44 systems in 2023, surpassing the goal of 30, and reaching a total installed base of 54 with a backlog of 9 systems as of December 31, 2023.
• Fourth quarter revenue reached $12.1 million, up from $10.2 million in the same period of 2022, primarily due to increased ALLY system sales and procedure volume.
• Full-year revenue totaled $42.2 million, compared to $35.4 million in 2022, with ALLY system sales being the largest contributor to the increase.
• Recurring revenue accounted for approximately 73% of total revenue in both Q4 2023 and 2022, and 77% and 86% for the full years 2023 and 2022 respectively.
• The company projects its recurring revenue base to be over $33 million in 2024, excluding any contribution from the South Korean market.
• Net loss for the fourth quarter was $3.9 million, or ($0.35) per share, compared to a net loss of $2.5 million, or ($0.24) per share, in Q4 2022.
• The full-year net loss was $14.4 million, or ($1.31) per share, compared to a net loss of $19.9 million, or ($1.96) per share, in 2022.
• EBITDA for the fourth quarter was ($3.2) million, and Adjusted EBITDA was ($1.2) million.
• Full-year EBITDA was ($11.6) million, and Adjusted EBITDA was ($4.5) million.
• As of December 31, 2023, the company had $24.6 million in cash, cash equivalents, and investments, compared to $14.7 million at the end of 2022.
• Worldwide procedure volume was impacted by reimbursement issues in South Korea, but excluding South Korea, procedure volume increased 15% in 2023.

Sentiment

Score: 8

Explanation: The document presents a positive outlook with strong revenue growth, exceeding placement targets, and improved cash position. However, the company is still operating at a loss, which tempers the overall sentiment.

Positives

• The company exceeded its ALLY placement target for 2023, demonstrating strong market adoption.
• LENSAR experienced significant revenue growth in both the fourth quarter and full year 2023.
• The majority of new LENSAR customers switched from competitive systems, indicating a competitive advantage.
• The company's recurring revenue base is projected to grow in 2024.
• Selling, general, and administrative expenses decreased, showing improved cost management.
• Research and development expenses decreased due to the ALLY System's FDA clearance, indicating a shift towards commercialization.
• The company's cash position improved significantly year-over-year.

Negatives

• The company experienced a net loss for both the fourth quarter and full year 2023.
• EBITDA and Adjusted EBITDA were negative for both the fourth quarter and full year 2023.
• Worldwide procedure volume was negatively impacted by reimbursement issues in South Korea.
• The percentage of revenue from recurring sources decreased from 86% in 2022 to 77% in 2023 due to higher ALLY sales.

Risks

• The company has a history of operating losses and needs to achieve and sustain profitability.
• The company's ability to commercialize the ALLY System and maintain the LENSAR Laser System is subject to regulatory risks.
• Global macroeconomic conditions could impact the company's business, financial condition, and results of operations.
• The willingness of patients to pay the price difference for LENSAR products compared to standard cataract procedures is a risk.
• The company's ability to grow its sales and marketing organization and maintain an effective network of international distributors is a risk.
• The company may need to raise additional funds, which may not be available on acceptable terms.
• Disruptions to the supply or manufacture of systems or component parts could impact the company.
• The company faces competition from companies with longer operating histories and greater resources.
• The company is exposed to credit risk from its customers.
• The company's ability to secure adequate coverage or reimbursement by third-party payors is a risk.
• The company is subject to product liability suits and government regulations.
• The company faces risks related to its intellectual property.

Future Outlook

The company intends to expand the ALLY installed base in the U.S. and launch in select international markets in 2024, subject to regulatory approvals. They also expect selling, general and administrative expenses to increase to support commercial expansion.

Management Comments

• Nick Curtis, President and CEO of LENSAR, stated that the company's strong performance continued in the fourth quarter, resulting in total revenue up 18% over the fourth quarter of 2022, with full-year revenue increasing 19%.
• Nick Curtis also expressed confidence that the ALLY's superior performance and efficiency will continue to drive more widespread adoption, solidifying the company's position as a leader in next-generation femtosecond laser cataract surgery technology.

Industry Context

The announcement reflects a positive trend in the medical technology sector, particularly in the area of advanced cataract treatment systems. The company's focus on innovative technology and international expansion aligns with broader industry trends towards improved surgical outcomes and global market reach.

Comparison to Industry Standards

• LENSAR's 19% revenue growth for the full year 2023 is strong compared to the overall medical device industry, which typically sees single-digit growth rates.
• The company's success in placing 44 ALLY systems in 2023, exceeding its target of 30, indicates a strong market acceptance of its technology, which is a positive sign compared to competitors in the femtosecond laser cataract surgery market such as Alcon and Johnson & Johnson Vision.
• The shift of new customers from competitive systems suggests a competitive advantage for LENSAR's ALLY system, which is a key differentiator in a market with established players.
• The company's focus on recurring revenue, which is projected to be over $33 million in 2024, is a positive indicator of long-term sustainability, which is a key metric for investors when compared to companies with a higher reliance on one-off sales.
• The decrease in research and development expenses after the FDA clearance of the ALLY system is a typical trend for medical device companies, indicating a shift from development to commercialization, which is a positive sign for investors.

Stakeholder Impact

• Shareholders will likely view the strong revenue growth and increased ALLY placements positively.
• Employees may benefit from the company's growth and expansion.
• Customers will have access to the company's advanced cataract treatment system.
• Suppliers may see increased demand for components used in the ALLY system.
• Creditors may view the improved cash position favorably.

Next Steps

• The company plans to continue expanding the ALLY installed base in the U.S.
• The company intends to launch the ALLY system in select international markets in 2024, subject to regulatory approvals.
• The company will continue to expand commercial efforts in the U.S. and internationally for the ALLY System.

Key Dates

Keywords

ALLY System, Cataract Treatment, Femtosecond Laser, Medical Technology, Revenue Growth, Financial Results, EBITDA, Regulatory Approvals, Procedure Volume, Installed Base